Harrow (HROW) Q4 2025 earnings review
Record Revenue and Cash Flow Reversal, Set Up for a Back-End Loaded 2026
Harrow delivered a strong finish to 2025, with Q4 revenue surging 33% YoY to $89.1M, capping off a year of massive sequential growth. While GAAP net income remained seemingly stagnant YoY at $6.6M, this was heavily penalized by an $8.5M upfront IPR&D charge for the Melt Pharmaceuticals acquisition. The most critical takeaway is the underlying operational transformation: full-year Operating Cash Flow reversed from negative $22.2M in 2024 to a robust positive $43.9M in 2025. Management's FY26 guidance projects $350-$365M in revenue, pointing to continued expansion, though a heavily H2-weighted forecast implies a sharp seasonal step-down in early 2026.
🐂 Bull Case
The company proved its commercial infrastructure can generate cash. Operating Cash Flow swung by over $66M YoY into positive territory, funding debt service and pipeline expansion internally.
VEVYE, IHEEZO, and TRIESENCE are all driving accelerating demand. The decision to double the VEVYE and TRIESENCE sales teams signals high confidence in immediate ROI and market share capture.
🐻 Bear Case
H1 2026 revenue guidance of $133-$153M implies an average of ~$71.5M per quarter—a severe sequential deceleration from Q4's $89.1M. This puts immense pressure on H2 execution to hit annual targets.
Total operating expenses in Q4 surged 38% YoY ($55.0M vs $39.8M), outpacing the 33% revenue growth. Expanding commercial footprints will continue to weigh on GAAP profitability in the near term.
⚖️ Verdict: 🟢
Bullish. Harrow has successfully transitioned from a cash-burning growth story to a cash-generating commercial engine. If the sales force expansion yields proportional VEVYE and TRIESENCE volume, the 2026 targets are highly achievable despite expected Q1 seasonality.
Key Themes
Explosive Operating Cash Flow Reversal
The most significant development in FY25 was the validation of Harrow's business model mechanics. Operating Cash Flow reversed dramatically, printing $+43.9M for the year compared to an alarming -$22.2M burn in FY24. This internally generated cash is crucial, as it allows the company to fund its aggressive sales force expansion and service its heavy debt load without diluting shareholders.
Doubling Down on the Commercial Footprint
Management announced they are doubling the sales teams for VEVYE and TRIESENCE while expanding IHEEZO into the office-based setting. This follows Q3's strategy of aggressively capturing market share after securing preferred formulary status for VEVYE with the largest U.S. PBM (effective Jan 2026). The expanded footprint is the primary engine behind the 31% implied revenue growth for 2026.
Severe Front-Half 2026 Deceleration Warning
While total FY26 guidance is strong, the breakdown is a glaring red flag for sequential momentum. Management guided H1 2026 revenue at $133-$153M. Even at the high end ($153M), this implies an average of $76.5M per quarter—a massive sequential step-down from Q4 2025's $89.1M. This confirms historical Q1 insurance deductible reset seasonality but bakes significant execution risk into the back half of the year ($203-$226M).
Melt Pharmaceuticals Integration and Pipeline Focus
Harrow formally absorbed Melt Pharmaceuticals, recording an $8.5M acquired IPR&D charge in Q4 that compressed GAAP net income. Management highlighted G-MELT (formerly MELT-300) and YOCHIL (formerly MELT-210) as large-market assets intended for launch beginning in 2028. This signals a strategic shift: Harrow is simultaneously scaling its current commercial bag while building a secondary launch wave to sustain growth post-2027.
Other KPIs
Stable. Gross margin held perfectly flat YoY at 79% for the fourth quarter, and FY25 gross margin held steady at 75%. This stability indicates that despite volume ramp-ups, supply chain and manufacturing costs are scaling efficiently.
Interest expense remains a heavy anchor on the bottom line, growing from $22.8M in 2024 to $24.2M in 2025. With $243M in loans payable on the balance sheet, Harrow's newly minted positive operating cash flow will be heavily relied upon for debt service.
Accelerating. SG&A jumped 24% YoY in Q4 to fund the broader commercial footprint. As management doubles the VEVYE and TRIESENCE sales forces in 2026, investors should expect this line item to remain elevated, testing the limits of their expected operating leverage.
Guidance
Decelerating growth rate but structurally massive. The midpoint ($357.5M) implies a 31% YoY growth rate. While this is lower than FY25's 36% growth, it represents over $85M in absolute incremental revenue, hinging on VEVYE payer coverage wins and TRIESENCE relaunch traction.
Accelerating profitability. The midpoint ($90M) implies a 45% YoY jump compared to the $61.9M achieved in 2025. This proves management's thesis that the infrastructure is 'paid for' and new revenue from the expanded sales team will drop efficiently to the bottom line.
Key Questions
Q1 2026 Sequential Trough
Your H1 2026 revenue guidance implies a severe sequential step-down from Q4's $89 million run rate. How much of this is driven by typical Q1 insurance deductible resets versus intentional destocking, and what gives you confidence in the massive H2 hockey-stick recovery required?
ROI on Commercial Buildout
You are doubling the VEVYE and TRIESENCE sales teams. What is the expected payback period for these new territories, and how much SG&A expansion is baked into the $80-$100M Adjusted EBITDA guidance?
Capital Allocation & Debt
Now that you have generated nearly $44M in operating cash flow, how do you prioritize debt paydown versus further pipeline acquisitions like Melt Pharmaceuticals over the next 12-24 months?